Abstract: There is provided a mechanical avatar assembly for use in a confined space in a structure. The mechanical avatar assembly includes a rail assembly for attachment to an access opening to the confined space. The rail assembly includes two or more rail segments coupled together to form an elongated base having a rail and a gear rack extending along a length of the elongated base. The rail assembly further includes a carriage portion coupled to the rail, and movable relative to the rail, and a drive assembly coupled to the carriage portion and to the gear rack, to move the carriage portion along the rail. The mechanical avatar assembly further includes an articulating avatar arm coupled to, and movable via, the carriage portion. The mechanical avatar assembly further includes an image capturing device.

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract: Systems and methods are provided to generate an access code specific to a user of an online marketplace to use to enter a first accommodation during a first reservation time frame and a second accommodation during a second reservation time frame and to send the access code specific to the user to a computing device at the first accommodation and a computing device at the second accommodation to use to enter the first accommodation during the first reservation time period and the second accommodation during the second reservation time period. The access code is automatically removed from the computing device at the first accommodation and the computing device at the second accommodation at the end of the first reservation time period and at the end of the second reservation time period, respectively.

Abstract: The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.

Abstract: A drying apparatus, particularly suitable for disposing water-containing organic waste. The drying apparatus includes a drying chamber with a circular cross-section, where waste enters the drying chamber through a waste inlet and undergoes rotational movement within the drying chamber due to a negative pressure generated by an air pump. The air pump draws out airflow from the drying chamber through an air duct connected to the flow outlet, ensuring that the waste continues to rotate during the drying process. Additionally, the apparatus is equipped with a microwave generating device, which directs microwaves into the drying chamber either directly or via a microwave conduit to efficiently dry the waste. This design combines the cyclonic motion with microwave heating, significantly enhancing drying efficiency and ensuring that the waste is fully dried in a short time, making it particularly suitable for disposing organic residue that requires rapid drying.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to a method and system for neuropsychological performance test, comprising A terminal device (101), used to interact with a cloud server (102) which stores user information and is logged into by user through the terminal device (101); the user information obtained by the terminal device (101) are input and stored to the cloud server (102) in a login state; a test module (400) comprises the user information, which is stored in the cloud server (102) or can be downloaded from the cloud server (102), and is directly accessed through said terminal device (101) and is trained by artificial neural network; and said user information comprises user biometrics or emotions identification information, neuropsychological performance test answers information, and user latency or user chronometrics information; and said terminal device (101) displays neuropsychological performance test results.

Abstract: A processing system, a method for obtaining using permission and a smart terminal based on generative artificial intelligence large language model (GAILLM) are provided. The processing system includes a smart terminal used to: when a request for using a GAILLM service of a user is obtained, determine whether the user has a permission to use the GAILLM service according to subscription information corresponding to identity of smart glasses of the user, allow the user to use the GAILLM service when the user has the permission, and output a notification message to notify the user to obtain the permission by performing a preset action when the user does not have the permission. The application improves the convenience of obtaining the permission to use the GAILLM service.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The invention provides compounds of formulae (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors; as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R, and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The invention provides compounds of formula (I), or pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit, CSF1R and PDGFR (PDGFR?, PDGFR?) kinases.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.

Abstract: A system for assessing a damage condition of a vehicle and a platform for facilitating repairing or maintenance services of a vehicle. The system comprises a damage identification module arranged to identify the one or more damages captured in a set of input images showing at least a portion of the vehicle; a component identification module arranged to identify one or more damaged components of the vehicle with the identified damages thereon; and an output module arranged to generate a damage assessment report associated with the identified damages and/or the identified damaged components of the vehicle.

Abstract: This invention provides a method for identifying a genetic trait of cells in a state of interest, a computer-implemented method for identifying a genetic trait of cells in a state of interest, a non-transitory computer-readable medium having stored thereon program instructions that, upon execution by a computing device, cause the computing device to perform operations for identifying a genetic trait of cells in a state of interest and a computing device comprising: 1) a processor; 2) memory; and 3) program instructions, stored in the memory, that upon execution by the processor cause the computing device to perform operations for identifying a genetic trait of cells in a state of interest.